



I hereby certify that this paper (along with any paper referred to as being attached and enclosed) is being deposited with the U.S. Postal Service as Express Mail, Label No. EM054394850US, on the date shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: July 23, 2007

Signature:

(Christina Andrews)

Docket No.: 47624DVC(71417)  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Jeffrey M. Isner et al.

Application No.: 10/714,574

Confirmation No.: 1777

Filed: November 14, 2003

Art Unit: 1633

For: **COMPOSITIONS AND METHODS FOR  
MODULATING VASCULARIZATION**

Examiner: Q. Nguyen

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications.

Copies of foreign patents and non-patent literature are not supplied because they were previously cited by or submitted to the Office in prior application numbers 09/698,323 filed October 27, 2000, 09/265,041 filed March 9, 1999, and 60/077,262

filed March 9, 1998 and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 04-1105 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 47624DVC(71417). A duplicate copy of this paper is enclosed.

Dated: July 23, 2007

Respectfully submitted,

By   
Melissa Hunter-Ensor, Ph.D.

Registration No.: 55,289

EDWARDS ANGELL PALMER & DODGE  
LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 517-5580

Attorneys/Agents For Applicant





Used in Lieu of PTO/SB/08A/B  
(Based on PTO 04-07 version)

Substitute for form 1449/PTO		<b>Complete if Known</b>	
		Application Number	10/714,574-Conf. #1777
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		Filing Date	November 14, 2003
		First Named Inventor	Jeffrey M. Isner
		Art Unit	1633
		Examiner Name	Q. Nguyen
Sheet	2	of	1
		Attorney Docket Number	47624DVC(71417)

CCE	Bevilacqua, M. P., Annu. Rev. Immuno., 11:767 (1993)
CCF	Brooks, P. C. et al., Science 264:569 (1994)
CCG	Civin, C.I. et al., J. Immunol. 133:157 (1984)
CCH	D'Amore, P. A. et al., Annu. Rev. Physiol. 49:453 (1987)
CCI	Dang et al., Clin. Canc. Resea. 5:471-474 (1999)
CCJ	Davis, et al., Hum Gene Ther., 4:151 (1993)
CCK	DeVries, C. et al., Science 255:989 (1992)
CCL	Felgner, P.L., et al., Nature 349:351-352 (1/24/91)
CCM	Ferrara, et al., Biochem. Biophys. Res. Commun., 161:851-855 (1998)
CCN	Ferrara, Trends Cardio. Med., 3:244-250 (1993)
CCO	Fina, J. et al., Blood 75: 2417 (1990)
CCP	Flamme I. Et al., Development, 116:435 (1992)
CCQ	Folkman, J. et al., Science 235:442 (1987)
CCR	Folkman, N. Engl. J. Med., 285:1182-1186 (1971)
CCS	Giodano et al., Nature Medicine 2: No.5 534-539 (Examiner cited)
CCT	Grant et al., Proc. Natl. Acad. Sci. 90:1937-1941 (1993) (Examiner cited)
CCU	His, W., Abhandl., K. S. Ges. Wiss. Math. Phys. 22, 171 (1900)
CCV	Houck, et al., Mol. Endocrinol., 8:1806-1814 (1991)
CCW	Jaffe, E. A. et al., J. Clin. Invest. 52:2745 (1973)
CCX	Joukou, et al., J. of Cell. Phys., 173:211-215 (1997)
CCY	Katz, F. et al., Leuk. Res. 9: 191 (1985)
CCZ	Kawakami et al., Brain Research Vol. 697:104-111 (1995) (Examiner cited)
CCCA	Kessinger A., et al., Blood, 77:211 (1991)
CCCB	Klagsbrun, et al., Annu. Rev. Physiol., 53:217-239 (1991)
CCCC	Matthews, W. et al., "A Receptor Tyrosine Kinase cDNA Isolated from a Population of Enriched Primitive Hematopoietic Cells and Exhibiting Close Genetic Linkage to c-kit" Proc. Natl. Acad. Sci. USA, 88:9026-9030 (1991).
CCCD	Miettinen, M. et al., Am. J. Clin. Pathol., 79:32 (1983)
CCCE	Nabel et al., Nature, 362:844(1993)
CCCF	Newman, P. J. et al., Science 247:1219 (1990)
CCCG	Pepper, M. S. et al., Biochem. Biophys. Res. Comm., 181:902 (1991)
CCCH	Polterak, et al., J. Biol. Chem., 272:7151-7158 (1997)
CCCI	Pu, et al., Circulation, 88:208-215 (1993)
CCCJ	Pu, et al., J. Surg. Res., 54:575-83 (1993)
CCCK	Risau, W. et al., Development 102, 471 (1998)
CCCL	Safi et al., J. Mol. Cell. Cardiol. 29:2311-2325 (1997) (Examiner cited)
CCCM	Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989)
CCCN	Sato, Y. et al., Exp. Cell Res. 204:223 (1993)
CCCO	Schaper, W. et al., Circ. Res. 28, 671 (1971)
CCCP	Schnurch, H. et al., Development 119, 957 (1993)
CCCQ	Sheridan, W. et al., Lancet 339:640 (1992)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Used in Lieu of PTO/SB/08A/B  
(Based on PTO 04-07 version)

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				Application Number	10/714,574-Conf. #1777
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Filing Date	November 14, 2003
				First Named Inventor	Jeffrey M. Isner
				Art Unit	1633
				Examiner Name	Q. Nguyen
Sheet	3	of	1	Attorney Docket Number	47624DVC(71417)

	CCCR	Shi et al., "Evidence fo Circulating Bone Marrow-Derived Endothelial Cells," Blood, 92:362-367 (1998).	
	CCCS	Shibuki, K. et al., Nature 358:676 (1991)	
	CCCT	Shpall, E.J. et al., J. Clin. Oncol, 12:28 (1994)	
	CCCU	Simmons, P. J. et al., Blood 80:388 (1992)	
	CCCV	Stratford-Perricaudet L.D., et al. J. Clin. Invest. 90:626-630 (1992)	
	CCCW	Symes et al., Current Opinion in Lipidology, 5:305-312 (1994)	
	CCCX	Takeshita, et al., Circulation, 90:228-234(1994)	
	CCCY	Takeshita, S, et al., Laboratory Investigation 74: 1061-1065 (1996)	
	CCCZ	Takeshita, S. et al., "Intramuscular Administration of Vascular Endothelial Growth Factor Induces Dose-Dependent Collateral Artery Augmentation in a Rabbit Model of Chronic Limb Ischemia." Circulation 1994 Nov;90(5 Pt 2):II228-34.	
	CCCCA	Terman, B. I. et al., Biochem. Biophys. Res. Commun. 187:1579 (1992)	
	CCCCB	Tischer, et al., J. Biol. Chem., 806:11947-11954 (1991)	
	CCCCC	Vitadello, M., et al., J. Clin. Invest. 90:626-630 (1992)	
	CCCCD	Weiss, M. et al., J. Clin. Invest., 97:591 (1996)	
	CCCCE	Witzenbichler et al. Chemotactic Properties of Angiopoietin-1 and -2, Ligands for the Endothelial-Specific Receptor Tyrosine Kinase Tie2. J. Biol. Chem 278:18514-18521, 1998.	
	CCCCF	Wolff, J.A. et al, Science 247:1465-1468 (1990)	
	CCCCG	Yanagisawa-Miwa, et al., "Salvage of Infarcted Myocardium by Angiogenic Action of Basic Fibroblast Growth Factor" Science, 257:1401-1403 (1992).	
	CCCCH	Yanagisawa-Miwa, et al., Science, 257:1401-1403 (1992)	
	CCCCI	Zollman, F. et al., Circulation (in press)	
	CCCCJ	Vitadello, M., et al., J. Clin. Invest. 90:626-630 (1992)	
	CCCCK	Weiss, M. et al., J. Clin. Invest., 97:591 (1996)	
	CCCCL	Witzenbichler et al. Chemotactic Properties of Angiopoietin-1 and -2, Ligands for the Endothelial-Specific Receptor Tyrosine Kinase Tie2. J. Biol. Chem 278:18514-18521, 1998.	
	CCCCM	Wolff, J.A. et al, Science 247:1465-1468 (1990)	
	CCCCN	Yanagisawa-Miwa, et al., "Salvage of Infarcted Myocardium by Angiogenic Action of Basic Fibroblast Growth Factor" Science, 257:1401-1403 (1992).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--